# Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer. Cost-effectiveness Analysis

> **NCT04283032** · — · UNKNOWN · sponsor: **InvestigatorUrologyIBSAL** · enrollment: 628 (estimated)

## Conditions studied

- Establish the Efficacy Between the Four Schemes in Terms of the Aggressiveness of the Tumors According to the Gleason Classification
- Establish the Efficacy Between the Four Schemes in Terms of Morbidity Associated With the Technique
- Establish the Efficacy Between the Four Schemes in Terms of the Patient's Subjective Perception Regarding Pain and Quality of Life
- Establish the Association of the Tumor Biomarker in the Early Detection and Aggressiveness of Tumors
- Establish the Possible Interaction Between Biomarkers and Resonance in Different Prostate Biopsy Models to Define Tumor Presence and / or Tumor Aggressiveness
- Establish the Possible Relationship Between the Expression Profiles of the microRNAs
- Establish if There Are Differences Between Transrectal and Transperineal Prostatic Biopsy Schemes in Both Cases With and Without MRI

## Interventions

- **PROCEDURE:** Multiparametric magnetic resonance

## Key facts

- **NCT ID:** NCT04283032
- **Lead sponsor:** InvestigatorUrologyIBSAL
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 628 (ESTIMATED)
- **Last updated:** 2020-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04283032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04283032, "Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer. Cost-effectiveness Analysis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04283032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*